Michael A Kolber
Overview
Explore the profile of Michael A Kolber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1033
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
da Fonseca Ferreira A, Wei J, Zhang L, Macon C, Degnan B, Jayaweera D, et al.
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108729
People living with HIV (PLHIV) are at a higher risk of having cerebrocardiovascular diseases (CVD) compared to HIV negative (HIV) individuals. The mechanisms underlying this elevated risk remains elusive. We...
2.
Tookes H, Oxner A, Serota D, Alonso E, Metsch L, Feaster D, et al.
Trials
. 2023 Feb;
24(1):96.
PMID: 36750867
Background: The resurgence of HIV outbreaks and rising prevalence among people who inject drugs (PWID) remain exigent obstacles to Ending the HIV Epidemic in the USA. Adapting a low threshold,...
3.
Martel-Laferriere V, Feaster D, Metsch L, Schackman B, Loignon C, Nosyk B, et al.
Trials
. 2022 Sep;
23(1):815.
PMID: 36167548
No abstract available.
4.
Harkness A, Wawrzyniak A, Kolber M, Villamizar K, Botero V, Rodriguez J, et al.
J Acquir Immune Defic Syndr
. 2022 Jun;
90(S1):S177-S189.
PMID: 35703770
Background: Rapidly linking newly diagnosed HIV patients to antiretroviral treatment (ART) is the best practice for achieving optimal treatment outcomes, including viral suppression. However, rapid ART implementation varies throughout the...
5.
Martel-Laferriere V, Feaster D, Metsch L, Schackman B, Loignon C, Nosyk B, et al.
Trials
. 2022 Apr;
23(1):341.
PMID: 35461260
Background: Opioid use is escalating in North America and comes with a multitude of health consequences, including HIV and hepatitis C virus (HCV) outbreaks among persons who inject drugs (PWID)....
6.
Martinez C, Rikhi R, Pester M, Parker M, Gonzalez A, Larson M, et al.
PLoS One
. 2022 Mar;
17(3):e0264445.
PMID: 35271614
Objective: Indices of cardiovascular disease (CVD) risk, vascular endothelial dilation, arterial stiffness and endothelial repair were examined in persons with HIV (PWH) on an antiretroviral therapy (ART) that included abacavir...
7.
Tookes H, Bartholomew T, Suarez E, Ekowo E, Ginoza M, Forrest D, et al.
Drug Alcohol Depend
. 2021 Nov;
229(Pt A):109124.
PMID: 34781096
Background: People who inject drugs (PWID) have been a marginalized and a stigmatized population since the beginning of the AIDS epidemic and have not experienced the same life-changing benefits of...
8.
Serota D, Tookes H, Hervera B, Gayle B, Roeck C, Suarez E, et al.
Ann Med
. 2021 Nov;
53(1):1960-1968.
PMID: 34726095
Introduction: Hospitalizations for severe injection-related infections (SIRI), such as endocarditis, osteomyelitis, and skin and soft tissue infections (SSTI) are increasingly common. People who inject drugs (PWID) experiencing SIRIs often receive...
9.
Tang E, Vittinghoff E, Philip S, Doblecki-Lewis S, Bacon O, Chege W, et al.
AIDS
. 2020 Mar;
34(8):1181-1186.
PMID: 32205724
Objective: The optimal screening frequency of sexually transmitted infections (STIs) for MSM and transgender women (TGW) on HIV pre-exposure prophylaxis (PrEP) is unclear, with present guidelines recommending screening every 3-6...
10.
Tookes H, Bartholomew T, Geary S, Matthias J, Poschman K, Blackmore C, et al.
AIDS Behav
. 2019 Sep;
24(1):246-256.
PMID: 31555932
Prevention of HIV outbreaks among people who inject drugs remains a challenge to ending the HIV epidemic in the United States. The first legal syringe services program (SSP) in Florida...